Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by golfpro2on Jan 03, 2011 9:41am

290 Views

Post# 17917796

RE: RE: RE: RE: When will they Quarter

I hope your right but from the tone of the analysts on the conference call, they will want to see at least 1-2 good quarters of profit to get the confidence back before we go much higher. i am thinking of adding at these levels and perhjaps the sub $1.00 may be gone but I am not sure I have to rush in. It may be at $1.00-1.10 for 2-3 months

Bullboard Posts

Three micro-cap value stocks trading at peak pessimism